Study summary

Venetoclax plus azacitidine remains the standard for older or unfit patients

VIALE-A long-term follow-up · 431 people, phase 3 · Published February 2024, American Journal of Hematology

What was tested

Long-term follow-up of venetoclax plus azacitidine against azacitidine alone for newly diagnosed AML in people unable to have intensive chemotherapy.

What they found

Survival benefit over azacitidine alone held up with longer follow-up.

What it means

The backbone that newer drugs are now being added to.

Am J Hematol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.